{"version":"1.0","provider_name":"JNNP blog","provider_url":"https:\/\/blogs.bmj.com\/jnnp","author_name":"Steve Vucic, Web Editor","author_url":"https:\/\/blogs.bmj.com\/jnnp\/author\/svucic\/","title":"Alemtuzumab: The new effective and safe frontier in active RRMS? - JNNP blog","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"aHGjIunByN\"><a href=\"https:\/\/blogs.bmj.com\/jnnp\/2014\/05\/23\/alemtuzumab-the-new-safe-frontier-in-rrms\/\">Alemtuzumab: The new effective and safe frontier in active RRMS?<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/blogs.bmj.com\/jnnp\/2014\/05\/23\/alemtuzumab-the-new-safe-frontier-in-rrms\/embed\/#?secret=aHGjIunByN\" width=\"600\" height=\"338\" title=\"&#8220;Alemtuzumab: The new effective and safe frontier in active RRMS?&#8221; &#8212; JNNP blog\" data-secret=\"aHGjIunByN\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/blogs.bmj.com\/jnnp\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"Alemtuzumab is a recently licensed monoclonal antibody directed against the CD52 antigen on lymphocytes.\u00a0 The efficacy of alemtuzumab has been established in phase II and III studies for RRMS, with spectacular reduction in relapse rates, although the disability reduction was better in the Phase II studies, where a reversal of disability was noted.\u00a0 Clearly, alemutuzumab [...]Read More..."}